Bayh-Dole Coalition, Author at The Bayh-Dole Coalition

WASHINGTON, D.C. (March 21, 2023) --Today, in response to the NIH's just-announced decision to reject activists' requests for the federal government to misuse "march-in" rights under the Bayh-Dole Act against the successfully developed prostate cancer drug Xtandi, Executive Director of the Bayh-Dole Coalition Joseph P. Allen released the following statement: ...

02 Mar Bayh–Dole Cannot be Used for Controlling Prices

Posted at 11:09h Other Media

Vital Health Podcast, 3/2/2023...

27 Feb Lawmakers and Patients Seek to Reduce Enzalutamide Cost

Posted at 14:07h Other Media

Kerry Dooley Young
Medscape, 2/24/2023...

25 Feb Bayh-Dole Coalition comments on USPTO Initiatives to Ensure the Robustness and Reliability of Patent Rights, 2/24/2023

Posted at 01:35h Public Comments, Resources

Author: Bayh-Dole Coalition

20 Apr Bayh-Dole Coalition Comments on Medicare Drug Price Negotiation Program, 4/14/2023

19 Apr Our National Security Depends on Intellectual Property

23 Mar Moderna Exec Stands By COVID-19 Vaccine Price Increase

23 Mar After Xtandi, Will Government Ever Seek March-In Rights Over Drug Pricing?

22 Mar NIH rejects bid to cut a cancer drug’s price by sidestepping patents

22 Mar Moderna Confronts ‘Poster Child’ Label as Price Crackdown Looms

21 Mar Bayh-Dole Coalition Statement on NIH Rejection of Xtandi March-in Petition

02 Mar Bayh–Dole Cannot be Used for Controlling Prices

27 Feb Lawmakers and Patients Seek to Reduce Enzalutamide Cost

25 Feb Bayh-Dole Coalition comments on USPTO Initiatives to Ensure the Robustness and Reliability of Patent Rights, 2/24/2023